| Abstrakt: |
A study conducted at Cedars-Sinai Medical Center examined the use of niraparib monotherapy as a first-line maintenance treatment for ovarian cancer patients. The study aimed to describe patient demographics, clinical characteristics, and clinical outcomes of patients receiving this treatment following combination chemotherapy plus bevacizumab. The study found that switch maintenance with niraparib monotherapy may be a viable treatment option for patients with advanced ovarian cancer. The research provides valuable insights into the real-world use of this therapy. [Extracted from the article] |
